广誉远(600771)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600771 广誉远

已收盘 07-24 15:00:00

{"stockData":{"symbol":"600771","market":"SH","secType":"STK","nameCN":"广誉远","latestPrice":13.94,"timestamp":1784876401000,"preClose":14.53,"halted":0,"volume":9231317,"delay":0,"changeRate":-0.0406,"floatShares":488999999,"shares":488999999,"eps":0.1353,"marketStatus":"已收盘","change":-0.59,"latestTime":"07-24 15:00:00","open":14.49,"high":14.67,"low":13.92,"amount":131000000,"amplitude":0.0516,"askPrice":13.94,"askSize":57,"bidPrice":13.93,"bidSize":243,"shortable":0,"etf":0,"ttmEps":0.1353,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"adjPreClose":14.53,"symbolType":"stock","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":15.98,"lowLimit":13.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":489491141,"isCdr":false,"pbRate":4.02,"roa":"--","peRate":103.030303,"roe":"4.01%","epsLYR":0.13,"committee":0.043745,"marketValue":6824000000,"turnoverRate":0.0189,"status":1,"floatMarketCap":6824000000},"requestUrl":"/m/hq/s/600771/tweets","defaultTab":"tweets","newsList":[{"id":"2653762802","title":"股市必读：广誉远（600771）7月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653762802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653762802?lang=zh_cn&edition=full","pubTime":"2026-07-23 01:15","pubTimestamp":1784740545,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，广誉远报收于14.67元，下跌0.81%，换手率2.4%，成交量11.77万手，成交额1.73亿元。广誉远近日对龟龄集也进行了提价，请问为何没有发布公告。公司严格遵守信息披露公平性原则，始终按照监管规则履行信息披露义务，所有达到法定披露标准的重大信息均通过指定信息披露渠道统一向全体投资者公开。公司重大诉讼进展公告均以法院正式法律文书或有效通知为客观依据，不存在应当披露而未披露或披露滞后的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300001326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653575641","title":"广誉远：公司严格遵守信息披露公平性原则","url":"https://stock-news.laohu8.com/highlight/detail?id=2653575641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653575641?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:48","pubTimestamp":1784713704,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月22日在投资者关系平台上答复投资者关心的问题。龟龄集是公司营收、毛利第一大单品，本次调价契合中医药优质优价政策，却仅对内通知渠道，散户只能从经销商处零散获取消息，信息披露有失公平。公司严格遵守信息披露公平性原则，始终按照监管规则履行信息披露义务，所有达到法定披露标准的重大信息均通过指定信息披露渠道统一向全体投资者公开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200036609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","600771"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653756410","title":"广誉远：个别药品品规在部分渠道的价格调整是公司的日常经营范畴","url":"https://stock-news.laohu8.com/highlight/detail?id=2653756410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653756410?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:45","pubTimestamp":1784713511,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月22日在投资者关系平台上答复投资者关心的问题。广誉远近日对龟龄集也进行了提价，请问为何没有发布公告。公司始终严格遵照监管要求履行信息披露义务，对个别药品品规在部分渠道的价格进行调整是公司的日常经营范畴，不涉及应披未披及其他违反监管规则的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200036474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","600771"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652783237","title":"每周股票复盘：广誉远（600771）涉9.34亿元诉讼上诉已受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2652783237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652783237?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:52","pubTimestamp":1784397133,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，广誉远报收于15.04元，较上周的14.23元上涨5.69%。本周，广誉远7月16日盘中最高价报16.03元。本周关注点公司公告汇总：广誉远因业绩承诺补偿纠纷上诉，涉案金额933,591,035.11元及利息，陕西省高院已受理。公司公告汇总广誉远中药股份有限公司因不服西安市中级人民法院关于业绩承诺补偿纠纷的一审判决，已提起上诉，请求判令对方支付补偿款利息及诉讼费用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600771","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651897184","title":"股市必读：广誉远（600771）7月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651897184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651897184?lang=zh_cn&edition=full","pubTime":"2026-07-15 04:27","pubTimestamp":1784060829,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，广誉远报收于15.1元，上涨0.33%，换手率3.27%，成交量16.03万手，成交额2.43亿元。董秘最新回复投资者： 当前整体消费环境偏弱，公司 7 月 1 日上调普通款龟龄集胶囊建议零售价，同时回收渠道全部低价库存。当日关注点交易信息汇总：7月14日主力资金净流出60.31万元，游资资金净流入1300.23万元。公司公告汇总：广誉远就业绩承诺补偿纠纷提起上诉，涉案金额933,591,035.11元及利息，陕西省高级人民法院已受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500005970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600771","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651179123","title":"广誉远（600771）披露重大诉讼进展公告，7月14日股价上涨0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651179123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651179123?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:32","pubTimestamp":1784021542,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，广誉远报收于15.1元，较前一交易日上涨0.33%，最新总市值为73.91亿元。该股当日开盘14.84元，最高15.44元，最低14.65元，成交额达2.43亿元，换手率为3.27%。近日，广誉远中药股份有限公司发布《关于重大诉讼的进展公告》。陕西省高级人民法院已受理该上诉案件。涉案金额合计933,591,035.11元及利息。公告指出，案件不会对公司损益产生负面影响，但最终影响以法院生效裁判为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400033949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600771","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651173989","title":"广誉远：公司核心产品遵循古法工艺，生产炮制周期较长","url":"https://stock-news.laohu8.com/highlight/detail?id=2651173989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651173989?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:03","pubTimestamp":1784016200,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月14日在投资者关系平台上答复投资者关心的问题。公司核心产品遵循古法工艺，生产炮制周期较长，从未对公司生产经营造成影响。公司近年来存货增长主要为贵细药材及在产品的战略性前置储备，是保障产品品质与长期供应的基础，不会对公司日常经营造成负面影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400029373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","600771","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651173602","title":"广誉远：酒剂车间设备更新提升自动化智能化水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2651173602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651173602?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:03","pubTimestamp":1784016200,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远(600771)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问：公司酒剂设备大规模采购，是现有产能停产了吗？是增加产能吗？广誉远回复：您好，感谢您的关注。公司现有酒类产品生产线正常运营，不存在停产情形。本次酒剂车间设备更新是公司践行“提质增效重回报”行动方案，基于统筹推进生产设备智能升级改造，促进生产提质增效，提升自动化、智能化水平，夯实经营质量根基，做好产能提升储备，增强供应链保障能力的举措之一。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400029374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","600771"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649675621","title":"股市必读：广誉远（600771）7月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649675621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649675621?lang=zh_cn&edition=full","pubTime":"2026-07-07 01:42","pubTimestamp":1783359733,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘，广誉远报收于14.26元，上涨0.92%，换手率1.99%，成交量9.73万手，成交额1.39亿元。本次调价预计对公司全年毛利率、净利润带来多大影响，为何未第一时间通过法定披露渠道向全体投资者公开？公司严格遵守信息披露公平性原则，不存在应披未披及其他违反监管规则的情形。2026年度毛利率、净利润等公司相关经营成果请关注后续的定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700000821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600771","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649464456","title":"广誉远：公司严格遵守信息披露公平性原则","url":"https://stock-news.laohu8.com/highlight/detail?id=2649464456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649464456?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:51","pubTimestamp":1783324270,"startTime":"0","endTime":"0","summary":"本次调价预计对公司全年毛利率、净利润带来多大影响，为何未第一时间通过法定披露渠道向全体投资者公开？公司严格遵守信息披露公平性原则，不存在应披未披及其他违反监管规则的情形。2026年度毛利率、净利润等公司相关经营成果请关注后续的定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600017902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","600771","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648651476","title":"广誉远：本次股东会已通过《关于使用公积金弥补亏损的议案》","url":"https://stock-news.laohu8.com/highlight/detail?id=2648651476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648651476?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:54","pubTimestamp":1783065265,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月03日在投资者关系平台上答复投资者关心的问题。投资者提问：本次年度股东大会表决结果显示，在持股 5% 以下的中小股东投票中，董事薪酬方案获反对票比例达 52.95%，同时 2025 年度利润分配预案、计提信用及资产减值损失议案的反对票比例均超 40%，集中反映出中小股东对管理层履职成效、公司分红安排、历史应收账款清收工作存在较多关切。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300026143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600771","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648323651","title":"广誉远：公司已围绕“科技创新”主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2648323651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648323651?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:37","pubTimestamp":1783064268,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月03日在投资者关系平台上答复投资者关心的问题。公司已围绕“科技创新”主线，结合行业环境、市场变化及实际发展情况在内部制定了相应量化目标。公司将严格按照规划方向稳步推进各项经营举措，全力推动营收与盈利持续改善，相关经营成果会在定期报告中及时披露，敬请广大投资者关注公司官方公告及定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300023555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648582651","title":"广誉远：以老字号品牌记忆与非遗工艺为抓手，针对性开展养生讲座、实地参观、产品体验推广等本土化深耕活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2648582651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648582651?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:37","pubTimestamp":1783064266,"startTime":"0","endTime":"0","summary":"建议依托老干局，以山西中药厂老品牌记忆为抓手，开展实地参观、养生讲座、体验推广等本土化深耕，低成本培育忠实用户。当前公司侧重高空品牌投放，忽视本土根据地建设，产品在山西认知度偏低。老字号复兴应守正出奇，先深耕山西离退休干部市场，做好地面渗透，方能逐步辐射全国老年市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300023549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","600771","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648065151","title":"广誉远：公司始终秉持进取发展的态度，绝不保守躺平","url":"https://stock-news.laohu8.com/highlight/detail?id=2648065151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648065151?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:37","pubTimestamp":1783064261,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2024年12月受处罚，3年内无法开展资本运作，到2026年12月才解禁。只有积极进取，股东们才会感谢你们的付出，躺平领高薪者请让位！公司始终秉持进取发展的态度，绝不保守躺平，后续将结合合规条件提前统筹谋划相关布局，在深耕主业、夯实经营基本面的基础上，稳步推进各项工作提质增效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300023530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648651390","title":"广誉远：现有AD研究属学术探索阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2648651390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648651390?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:37","pubTimestamp":1783064255,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月03日在投资者关系平台上答复投资者关心的问题。现有AD研究属学术探索阶段，与注册申报标准确有差距。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300023515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","600771","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648265135","title":"广誉远：公司控股股东高度重视上市公司控制权稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2648265135","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648265135?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:37","pubTimestamp":1783064250,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远07月03日在投资者关系平台上答复投资者关心的问题。投资者提问：山西广誉远国药为上市公司核心生产子公司，晋中国资持有其约 3.97% 股权，当前公司控股股东神农科技集团持股仅 15.17%，控股比例偏低。公司控股股东高度重视上市公司控制权稳定，此前已通过实施股份增持进一步夯实控股地位，所有涉及上市公司资本运作类事项，公司将及时合规履行信息披露义务，请关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300023499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","600771","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647088963","title":"广誉远（600771）披露2025年年度股东会法律意见书，6月29日股价上涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647088963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647088963?lang=zh_cn&edition=full","pubTime":"2026-06-29 22:43","pubTimestamp":1782744195,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，广誉远报收于13.38元，较前一交易日上涨5.27%，最新总市值为65.49亿元。近日，广誉远披露北京海润天睿律师事务所关于公司2025年年度股东会的法律意见书。公告显示，该所确认广誉远中药股份有限公司2025年年度股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果均符合相关法律法规及《公司章程》规定，会议决议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900041526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600771","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646733778","title":"广誉远：公司已于2023年实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2646733778","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646733778?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:18","pubTimestamp":1782461907,"startTime":"0","endTime":"0","summary":"证券之星消息，广誉远06月26日在投资者关系平台上答复投资者关心的问题。您的“公司仍存在大额亏损”信息并不准确，公司已于2023年实现扭亏为盈，此后也持续保持盈利。当前公司正处于经营修复和深化发展的关键阶段，管理层将持续深耕中药主责主业，全力巩固经营向好态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646337762","title":"广誉远：所有诉讼案件均严格按照披露标准进行披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2646337762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646337762?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:18","pubTimestamp":1782461907,"startTime":"0","endTime":"0","summary":"针对前述信息披露违法违规事项的相关情况均第一时间公告，依法履行了信息披露义务。公司始终高度重视全体股东的知情权和合法权益，所有诉讼均有专业人员跟进，公司严格及时履行信息披露义务，不存在应披未披事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","600771"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646337719","title":"广誉远：西黄丸、感冒清热颗粒尚未形成规模化销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2646337719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646337719?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:18","pubTimestamp":1782461901,"startTime":"0","endTime":"0","summary":"公司控股子公司山西广誉远国药生产的西黄丸、感冒清热颗粒中选全国中成药集采后，公司正积极推进相关落地执行工作，但该工作受各省集采实施节奏、院内入院流程周期等因素影响，当前两款产品尚未形成规模化销售，此两款产品公司仍采取先款后货销售方式，不会存在应收账款，集采业务对公司2026年度经营业绩影响需以后期实际销售情况为准，存在一定不确定性，请您关注公司后续披露的定期报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784886757659,"stockEarnings":[{"period":"1week","weight":-0.081},{"period":"1month","weight":0.0491},{"period":"3month","weight":-0.1478},{"period":"6month","weight":-0.1981},{"period":"1year","weight":-0.3081},{"period":"ytd","weight":-0.1919}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0498},{"period":"6month","weight":-0.0627},{"period":"1year","weight":0.0822},{"period":"ytd","weight":-0.0232}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广誉远中药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"65920人(较上一季度增加2.20%)","perCapita":"7425股","listingDate":"1996-11-05","address":"山西省晋中市太谷区广誉远路1号","registeredCapital":"48949万元","survey":"　　广誉远中药股份有限公司的主营业务是中药产品的生产与销售。公司的主要产品是龟龄集、定坤丹大蜜丸、定坤丹水蜜丸、定坤丹口服液、安宫牛黄丸、牛黄清心丸、加味龟龄集酒、远字牌龟龄集酒。公司产品先后获得“山西精品”认定，六味地黄丸传统制作技艺及姜炭制作技艺入选晋中市非物质文化遗产名录。","listedPrice":4.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"广誉远(600771)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供广誉远(600771)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"广誉远,600771,广誉远股票,广誉远股票老虎,广誉远股票老虎国际,广誉远行情,广誉远股票行情,广誉远股价,广誉远股市,广誉远股票价格,广誉远股票交易,广誉远股票购买,广誉远股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"广誉远(600771)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供广誉远(600771)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}